Doyle Wealth Management lowered its stake in Becton Dickinson and Co (NYSE:BDX) by 11.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,299 shares of the medical instruments supplier’s stock after selling 301 shares during the period. Doyle Wealth Management’s holdings in Becton Dickinson and were worth $492,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Sii Investments Inc. WI increased its holdings in Becton Dickinson and by 2.2% during the 2nd quarter. Sii Investments Inc. WI now owns 1,738 shares of the medical instruments supplier’s stock valued at $342,000 after purchasing an additional 38 shares during the period. Quadrant Capital Group LLC increased its holdings in Becton Dickinson and by 0.5% during the 2nd quarter. Quadrant Capital Group LLC now owns 9,960 shares of the medical instruments supplier’s stock valued at $1,925,000 after purchasing an additional 45 shares during the period. WFG Advisors LP increased its holdings in Becton Dickinson and by 0.9% during the 2nd quarter. WFG Advisors LP now owns 5,376 shares of the medical instruments supplier’s stock valued at $1,049,000 after purchasing an additional 48 shares during the period. Aureus Asset Management LLC increased its holdings in Becton Dickinson and by 5.6% during the 2nd quarter. Aureus Asset Management LLC now owns 1,695 shares of the medical instruments supplier’s stock valued at $331,000 after purchasing an additional 90 shares during the period. Finally, Quantum Capital Management increased its holdings in Becton Dickinson and by 7.3% during the 2nd quarter. Quantum Capital Management now owns 1,499 shares of the medical instruments supplier’s stock valued at $292,000 after purchasing an additional 102 shares during the period. Hedge funds and other institutional investors own 75.56% of the company’s stock.
Becton Dickinson and Co (BDX) opened at $218.89 on Tuesday. Becton Dickinson and Co has a twelve month low of $175.66 and a twelve month high of $248.39. The company has a current ratio of 1.54, a quick ratio of 0.93 and a debt-to-equity ratio of 1.04. The firm has a market capitalization of $57,811.89, a P/E ratio of 22.52, a price-to-earnings-growth ratio of 1.49 and a beta of 1.12.
Becton Dickinson and (NYSE:BDX) last posted its earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share for the quarter, topping analysts’ consensus estimates of $2.41 by $0.07. Becton Dickinson and had a return on equity of 16.19% and a net margin of 2.71%. The firm had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $3.05 billion. During the same quarter in the prior year, the business earned $2.33 EPS. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. sell-side analysts expect that Becton Dickinson and Co will post 10.95 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, March 30th. Shareholders of record on Friday, March 9th will be issued a dividend of $0.75 per share. The ex-dividend date of this dividend is Thursday, March 8th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.37%. Becton Dickinson and’s dividend payout ratio (DPR) is 229.01%.
In other Becton Dickinson and news, Director Timothy M. Ring sold 269,661 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $217.82, for a total transaction of $58,737,559.02. Following the transaction, the director now owns 295,753 shares in the company, valued at approximately $64,420,918.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.00% of the stock is currently owned by corporate insiders.
A number of brokerages recently issued reports on BDX. Royal Bank of Canada restated a “hold” rating and set a $210.00 price target on shares of Becton Dickinson and in a report on Wednesday, October 25th. Zacks Investment Research upgraded Becton Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 price target on the stock in a report on Tuesday, October 31st. Piper Jaffray Companies restated an “overweight” rating and set a $260.00 price target (up previously from $223.00) on shares of Becton Dickinson and in a report on Tuesday, February 6th. Citigroup upgraded Becton Dickinson and from a “sell” rating to a “neutral” rating in a report on Friday, January 5th. Finally, Morgan Stanley boosted their price target on Becton Dickinson and from $245.00 to $250.00 and gave the company an “equal weight” rating in a report on Wednesday, February 7th. Four analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. Becton Dickinson and presently has an average rating of “Buy” and a consensus target price of $237.27.
WARNING: This piece of content was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/13/doyle-wealth-management-has-492000-stake-in-becton-dickinson-and-co-bdx.html.
Becton Dickinson and Company Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.